Mechanism of Action
- Inhibits NNMT enzyme in adipose tissue
- Increases NAD+ and SAM levels in cells
- Restores proper energy metabolism
Research scope
- Adipose tissue reduction via NNMT enzyme inhibition
- Metabolic support in obesity and lipid disorders
- Improved mitochondrial function and biogenesis
- Potential cardioprotection (HFpEF model)
Introduction
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme involved in NAD+ metabolism and adipose tissue regulation.
Preclinical data suggests that NNMT inhibition may improve metabolic flexibility and reduce fat accumulation by preserving intracellular NAD+ pools. The strongest evidence so far comes from animal and cell models, so this should be read as a research review, not a clinical recommendation.
Mechanism of Action
5-Amino-1MQ works by selectively inhibiting the NNMT enzyme, which leads to:
- Increased NAD+ availability
- Improved cellular energy metabolism
- Enhanced mitochondrial function
Research Applications
Current research focuses on:
- Metabolic disorders
- Obesity management
- Cardiovascular health
- Aging and longevity
In murine obesity models, NNMT inhibition was associated with lower adipose mass and improved metabolic signaling. The main hypothesis is straightforward: when NNMT activity drops, cells waste less nicotinamide on methylation and retain more substrate for NAD+-dependent energy pathways.
Safety Profile
Human evidence remains limited. The mechanistic rationale is strong, but 5-Amino-1MQ is still best understood as an experimental metabolic compound rather than a validated therapeutic option.
Conclusion
5-Amino-1MQ is one of the more interesting NNMT-targeting compounds in the current longevity and obesity research landscape. Its appeal comes from a clean mechanistic story, but translation from preclinical promise to real-world human outcomes is still an open question.